id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0261-0005,FDA,FDA-2003-E-0261,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-06-28T04:00:00Z,2004,6,,,2025-10-24T22:10:29Z,,0,0,0900006480490369
FDA-2003-E-0261-0004,FDA,FDA-2003-E-0261,Determination of Regulatory Review Period for Purposes of Patent Extension; LEXAPRO,Notice,General Notice,2003-12-02T05:00:00Z,2003,12,2003-12-02T05:00:00Z,,2025-10-24T22:03:18Z,03-29927,0,0,0900006480490349
FDA-2003-E-0261-0003,FDA,FDA-2003-E-0261,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-11-12T05:00:00Z,2003,11,,,2025-10-24T21:57:45Z,,0,0,0900006480490347
FDA-2003-E-0261-0002,FDA,FDA-2003-E-0261,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-10-06T04:00:00Z,2003,10,,,2025-10-24T21:54:17Z,,0,0,0900006480490344
FDA-2003-E-0261-0001,FDA,FDA-2003-E-0261,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-06-06T04:00:00Z,2003,6,,,2025-10-24T21:51:45Z,,0,0,09000064804902da